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Objective: To assess the therapeutic effects of oral zileuton tablets combined with low-
dose beclomethasone compared to doubling the dose of beclomethasone, in improving
lung function and reducing asthma symptoms.
Methods: Randomized, active-control, double-blind, parallel, multi-center study of
zileuton (400 or 600mg QID)+200 mg beclomethasone dipropionate (BDP) BID versus
placebo+BDP 400 mg BID in asthmatics with baseline FEV1 percent predicted values
between 40% and 80% following a single-blind ICS (BDP 200 mg BID) 2-week run-in. During
the 3-month double-blind treatment period, assessments included safety, daytime and
nighttime symptoms, acute asthma exacerbations, b2-agonist use, AM and PM peak
expiratory flow (PEF) and FEV1.
Results: The addition of a 5-lipoxygenase (5-LO) inhibitor added to a low-dose of BDP
showed no significant difference in FEV1 compared to doubling the dose of BDP. FEV1
improved in all 3 treatment groups, with mean increases of 10% with zileuton 600mg
QID+BDP 200 mg BID, 12% with zileuton 400mg QID+BDP 200 mg BID, and 11% with BDP 400 mg
BID by study end. Within each treatment group, there were significant improvements in
asthma symptoms and AM and PM PEF compared to baseline. No significant differencesElsevier Ltd. All rights reserved.
668 8279; fax: +1 919 668 7023.
kcl.ac.uk (B.J. O’Connor), claes-goran.lofdahl@med.lu.se (C-G. Lo¨fdahl), mbalter@mtsina.on.ca
A. Szczeklik), louis-philippe.boulet@med.ulaval.ca (L.-P. Boulet), charles.cairns@duke.edu
ARTICLE IN PRESS
Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma 1089were observed between groups with regards to salbutamol use, acute asthma exacerba-
tions, the requirement for oral/parenteral corticosteroids and adverse clinical events.
Conclusions: The addition of a 5-LO inhibitor added to low-dose beclomethasone may be
an alternative to higher-doses of ICS in patients unable to achieve sufficient asthma control
on low-dose ICS therapy.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Asthma is a heterogeneous chronic inflammatory disease
requiring anti-inflammatory therapy to achieve asthma
control.1,2 Responsiveness to treatment is heterogeneous,
even among asthmatic patients with asthma of similar
severity and this heterogeneity calls attention to the
importance of assessing asthma control and adjusting
treatment accordingly.3
Inhaled corticosteroids (ICS) are recommended as a first-
line treatment for asthma not controlled by short-acting
b2-agonists alone (SABAs).
1,2,4 Recent studies demonstrate
that increasing doses of ICS result in increased systemic
absorption while not necessarily improving lung function,
with only a third of patients demonstrating greater than a
15% improvement in lung function.5,6 Furthermore, the
potential for systemic side effects with higher doses of ICS
and the relatively flat dose–response curves led to the
universal asthma treatment guideline recommendation of
using the lowest effective dose of ICS to control asthma.1,2
Current asthma treatment guidelines also suggest that
patients uncontrolled on ICS therapy alone should receive
additional therapy.4 The most common additional agents
added to inhaled steroids are long-acting b2-agonists
(LABAs). The addition of a fixed-dose combination of an
ICS and a LABA can result in reduced exacerbations,
improved lung function and a reduction in the need for
rescue medication.7
However, recent studies have suggested that 30% of
asthmatics receiving combination therapy with a combina-
tion of an ICS and a LABA still remain inadequately
controlled, even with specialty care.8–10 Reasons cited for
these findings include insufficient patient education, poor
medication compliance, environmental factors, poor inhala-
tion technique and smoking. In addition, the presence of
b2-adrenergic receptor polymorphisms have been associated
with deleterious responses to regular administration of both
SABAs and LABAs.11,12 Importantly, inappropriate use of
LABAs has also been associated with increased asthma-
related mortality and cardiovascular effects in susceptible
populations.8,9
Another complementary approach to asthma therapy is
to modulate leukotriene production.13–34 Leukotrienes
synthesized via the 5-LO pathway include the cysteinyl
leukotrienes (LTC4, LTD4, and LTE4), 5-oxo-6,8,11,14-eico-
satetraenoic acid (5-oxo-ETE) and leukotriene B4 (LTB4).
While the leukotriene receptor antagonists, zafirlukast and
montelukast, antagonize only the cysteinyl leukotriene
receptor one (cysLT1R) and mediate the effects of the
cysteinyl leukotrienes,35 the 5-LO inhibitor zileuton blocks
the synthesis of the cysteinyl leukotrienes, 5-oxo-ETE and
LTB4.
23,36The importance of LTB4 blockade stems from its role as a
potent chemoattractant for inflammatory cells, such as
T-effector cells, eosinophils, and neutrophils.24–26 Indeed,
LTB4 is the major 5-LO product of neutrophils, monocytes,
and alveolar macrophages.20 LTB4 stimulates leukocyte
chemotaxis, chemokinesis and vascular endothelium adher-
ence, delays neutrophil apoptosis and prolongs neutrophil
survival.24
Another key 5-LO product, 5-oxo-6,8,11,14-eicosatetrae-
noic acid (5-oxo-ETE), is a chemoattractant for eosinophils,
over 30 times more potent than the cysteinyl leukotrienes,
and leads to the migration of eosinophils and prolonged
eosinophil survival. 5-oxo-ETE also activates neutrophils,
stimulates neutrophil degranulation and induces potent
basophil migratory responses.37,38
Recent reports have suggested that neutrophils may play
an important role in asthma, particularly severe and
difficult-to-treat populations.31,32 Indeed, neutrophilic in-
flammation has been shown to be increased in multiple
asthma phenotypes, including severe, acute, fatal, sudden-
onset, occupational and smoking asthmatics with a corre-
sponding increase in neutrophil numbers and activation
states.28,32,39–41 Corticosteroids have been reported to
suppress neutrophil apoptosis and their use may increase
neutrophil numbers.38,42,43 LTB4, a potent neutrophil che-
moattractant, is increased in the brochoalveolar lavage
(BAL) fluid, sputum and tissue of severe asthmatics and the
levels remain high despite corticosteroid therapy.27,29,32,42
The relative insensitivity of the 5-LO pathway to corticos-
teroid therapy, increased 5-LO products in asthmatic
inflammation and increased neutrophilic inflammation sup-
port the rationale for the combination of a 5-LO inhibitor
added to an ICS.
Zileuton, a benzothiophene N-hydroxyurea, is a selective
inhibitor of 5-LO. In controlled clinical studies in patients
with persistent asthma, zileuton improved pulmonary
function and asthma symptom scores significantly and
reduced the need for b2-agonist use and systemic corticos-
teroid rescue for acute asthma exacerbations.44,45
This randomized, active-control, double-blind, parallel,
multi-center study was designed to evaluate the effect of
zileuton plus low-dose beclomethasone compared with
doubling the dose beclomethasone in asthmatics inade-
quately controlled with the regular use of ICS.Materials and methods
Patients
Asthmatics either not currently treated with ICS or those on
a stable dose of BDP were recruited for enrollment in the
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ages of 16 and 70, baseline FEV1 within 40–80% of predicted
values on ICS and 15% reversibility after salbutamol.
Exclusion criteria included the use of oral corticosteroids
or ICS (4600 mg BDP or equivalent), inhaled cromolyn,
nedocromil, theophylline products, long-acting antihista-
mines, aspirin or other non-steroidal anti-inflammatory
agents, phenytoin or warfarin, anticholinergic eyedrops or
inhalation therapy, oral salbutamol or LABAs. Patients were
permitted to use nasal corticosteroids during the study and
undergo immunotherapy if they entered the study on a
stable dose/regimen.Study protocol
This was a randomized, active-controlled multi-center study
with a 2-week, single-blind run-in period followed by a 12-
week double-blind treatment period. Efficacy assessments
included FEV1, morning (AM) and evening (PM) PEF, daily and
nocturnal asthma symptom scores, b2-agonist use, and the
frequency of acute asthma exacerbations.
Patients had to meet the single-blind selection criteria to
enter the study. Study drugs during the single-blind period
were 2 matching placebo tablets, BDP (400 mg daily) and
placebo inhalers. During the run-in period patients were
required to complete patient diaries; patients who complied
with the patient diary and pill regimen and who then met
the double-blind selection criteria (including FEV1, symptom
scores, and rescue medication use) were randomized into
the double-blind period.
During the double-blind period patients received 1 of 3
treatments: zileuton 2400mg taken as 600mg tablets 4
times a day (QID) plus inhaled BDP 400 mg (200 mg [2 puffs]
BID) daily; zileuton 1600mg (400mg QID) plus inhaled
BDP 400 mg (200 mg BID) or placebo tablets plus inhaled
BDP 800 mg (400 mg [4 puffs] BID) daily—hereafter referred
to as Z 2400mg+B 400 mg, Z 1600mg+B 400 mg, and Pl+B
800 mg. Results from the initial zileuton phase I studies
indicated that both of these doses of zileuton were well
tolerated and would provide significant LTB4 inhibition
(70–90%).
Safety assessments included physical examination, med-
ical history, chest radiograph, electrocardiogram, routine
blood chemistry panel, vital signs, and hematology tests.
On the first day of the double-blind period zileuton or
placebo was administered and FEV1 measured at baseline
and 30min post-dose. At subsequent visits, FEV1 was
measured after the morning dose, AM PEF was measured
each morning prior to the first dose of study drug and PM PEF
measurements were obtained 2 h after the third dose each
evening. Patients completed diaries and recorded morning
and evening scores, based on wheezing, shortness of breath,
cough, and nasal congestion. Patients also recorded their
salbutamol use, other concomitant medication use, and any
adverse events during the previous 24-h period. Study visits
were scheduled for Days 15, 43, 71 and 85 of the double-
blind treatment period.
The protocol permitted a 1-week course of oral pre-
dnisone at a tapered dose (p60mg/day forp7 days) for any
acute asthma exacerbations not responding to salbutamol or
antibiotics for suspected respiratory infections.Compliance with dosing regimens was monitored. Patients
were instructed to return all unused tablets and inhalers to
the study center at every visit. Study personnel verified
patient compliance through counts of the unused tablets
and by the patient’s record of inhaler use in the patient’s
diaries. At each visit, the study drug supplies were dispensed
and the date and time of the first and last administered dose
(for both tablets and inhalers) and the number of tablets
remaining after the last dose were recorded on the case
report form. Zileuton plasma levels provided an additional
check of compliance.Statistical analysis
The primary efficacy variable was the percent change from
baseline to the final visit in morning FEV1. Sample size
requirements for a superiority study were calculated from a
previous 1-month study of zileuton versus placebo in asthma
that demonstrated an improvement in FEV1 of 0.19 L with
zileution.46 Based on a calculated standard deviation of
0.48 L for the change from baseline in FEV1, it was estimated
that 100 patients per treatment group would be required to
provide a power of 80% at the 2-sided 0.050 level for a pair-
wise comparison between a zileuton plus BDP group and the
Pl+B 800 mg group, assuming that the expected difference
between these 2 groups was 0.19 L for the change from
baseline. The primary comparison for this study was Z
2400mg+B 400 mg versus Pl+B 800 mg for mean percent
change from baseline to the final visit.
Statistical analyses were performed using SASs for
Windows. Unless otherwise noted, inferential treatment
comparisons were declared statistically significant at the 5%
level using 2-sided tests. Efficacy analyses were based on
the intent-to-treat population using a last value carried
forward convention. Data from investigative sites with less
than 2 subjects for each treatment group were pooled into a
single ‘‘site.’’
Baseline values for non-diary data were obtained by
selecting the final measurement prior to the first adminis-
tration of double-blind study drug. Baseline values of the
diary data were obtained by computing the mean of the
diary data collected during the single-blind lead-in phase.
For all analyses, summary statistics were based only on
patients for whom there was both a baseline value and a
double-blind interval value.
Double-blind data best corresponding to the nominal visit
day from the appropriate ‘‘intervals’’ were used, but data
obtained more than 3 days after the end of double-blind
dosing were not used. When more than 1 value was of equal
proximity to the nominal visit day, the later value was
selected. The ‘‘final’’ treatment measurement was obtained
using the last data measurement not later than 3 days after
the end of the double-blind dosing.
A 2-way analysis of variance was performed with effects
for treatment and investigator in the model to test
differences between treatment groups for efficacy end-
points. Additionally, a model with investigator, treatment
and investigator–treatment interaction was fit to investigate
whether the treatment effect was homogenous across
investigative sites. If investigator–treatment interaction
was significant (using a ¼ 0.100) by-site analyses were
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formed on analyses of secondary outcomes.
Analysis of safety data was based on all data from all
patients who entered the double-blind period. Adverse
events were coded by COSTART body system, COSTART term
and COSTART medical term. Adverse events having an onset
later than 14 days after the end of treatment were not
included in frequency tabulations (Table 1).Results
Subjects
Three hundred and eighty-eight patients entered the
single-blind phase of the study and 320 qualified for the
double-blind period. These patients were randomized to 3
groups across 32 centers: Z 1600mg+400 mg BDP (n ¼ 108), Z
2400mg+B 400 mg (n ¼ 110) and Pl+B 800 mg (n ¼ 102).
Two hundred and seventy patients (84%) completed the
study. Fifty patients discontinued the double-blind
treatment prematurely: 14 in the Z 1600mg+400 mg B, 20
in the Z 2400+B 400 mg and 16 in the Pl+B 800 mg groups,
respectively.
There were no clinically significant differences between
treatment groups (Table 2) with respect to demographic
characteristics. Baseline values (prior to randomization) for
pulmonary function, symptom scores and salbutamol use
were similar among groups, although the Z 2400mg+B 400 mg
group had lower baseline AM and PM PEF rates than both the
Z 1600mg+B 400 mg and the B 800 mg+Pl treatment groups.
At the time of randomization, patients still had reduced lung
function and were symptomatic.Table 1 Assessments of daily asthma symptoms completed by
Daytime symptoms (recorded each evening)
0 No Symptoms, unrestricted activity
1 Symptoms present but produce little or no discomfort;
2 Symptoms present, sometimes causing annoyance or im
3 Symptoms severe, improving little after inhaled use an
visit
Nocturnal symptoms (recorded each morning)
0 Slept well, no asthma symptoms
1 Spent restless night, may have awakened due to asthm
2 Awakened more than once due to symptoms, inhaler u
3 Awake all night due to symptoms, inhaler used
Criteria for diagnosis of asthma exacerbations (1 or more requir
1 Decrease in PEF of X20% from previous visit
2 Increase of X25% in daily PEF variations
3 Daily use of X12 puffs of salbutamol
4 Relief provided by administered medications did not la
5 Score of 35 exceeded on four asthma assessment score
6 Maximum score of 3 on daytime and 2 on nocturnal sym
These criteria were applied at Canadian sites only. At European
clinical judgment of the investigator, i.e., whether the patient had a
an acute exacerbation of asthma.Pulmonary function
All the 3 treatment groups demonstrated statistically
significant improvement from baseline in FEV1 at all visits
(rp 0.050). In the Z 2400mg+B 400 mg treatment group, the
greatest mean percent improvement occurred at Day 85
(10%); in the Z 1600mg+B 400 mg group and the Pl+B 800 mg
group, the greatest mean percent improvements occurred
at Day 71 (11% and 13%, respectively) (Fig. 1). There were no
statistically significant differences in FEV1 between any pair
of treatment groups at any visit.
Both of the zileuton groups, Z 2400mg+B 400 mg and Z
1600mg+B 400 mg, had statistically significant mean im-
provements from baseline in AM and PM PEF values at all
study intervals (rp0.050). The mean improvements from
baseline in PM PEF for the Z 2400mg+B 400 mg group were
statistically significant at almost all intervals except Day
30–57. Generally, the mean improvements from baseline in
AM and PM PEF rates were higher for the Z 2400mg+B 400 mg
and the Z 1600mg+B 400 mg treatment groups than for the
Pl+B 800 mg group. The mean improvement from baseline in
PM PEF was lower for Z 1600mg+B 400 mg than for the Pl+B
800 mg only during the double-blind Day 30–57 interval.
There was a statistically significant difference between the
Z 2400mg+B 400 mg and Pl+B 800 mg treatment groups in AM
PEF during the double-blind Day 79–99 interval (31.14 versus
16.31 L/min, p ¼ 0.033, Fig. 2). In addition, there were
statistically significant differences between Z 2400mg+B
400 mg and the Pl+B 800 mg treatment groups in PM PEF
during the double-blind Day 1–29 (15.35 versus 6.68 L/min,
p ¼ 0.046), 58–78 (23.43 versus 9.90 L/min, p ¼ 0.036)
and 79–99 (24.52 versus 8.94 L/min, p ¼ 0.019) intervals
(Fig. 3).patients.
activity unrestricted
pairing routine activity such as dressing, walking, etc.
d requiring the use of additional medication and/or doctor’s
a symptoms; may have used inhaler
sed
ed)
st at least 3 h
s over 3-day period
ptoms over any 24-h period
sites, asthma exacerbation was determined by the subjective
worsening of symptoms sufficiently pronounced to be considered
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Table 2 Demographic and baseline characteristics of asthma patients.y
Parameters Z 2400mg+B 400 mg Z 1600mg+B 400 mg Pl+B 800 mg
Age (yrs) 3971.3 3671.3 3771.3
Gender
Female 57 (53) 44 (40) 43 (42)
Male 51 (47) 66 (60) 59 (58)
Race
White 102 (94) 101 (92) 101 (99)
Black 2 (2) 5 (5) 1 (1)
Other 4 (4) 4 (4) 0
FEV1 (L) 2.1870.08
z 2.4270.08 2.3670.08
FEV1 (% predicted) 62.371.3 64.371.3 63.171.3
AM PEF (L/min) 346711y 388712 380712
PM PEF (L/min) 376711z 417712 407 712
Daily Symptoms [0 (none) to 3 (worst)] 1.1970.04 1.1870.04 1.1470.04
Nocturnal Symptoms [0 (none) to 3 (worst)] 0.5770.06 0.6470.06 0.4370.06
Salbutamol use (puffs/day) 2.6770.3 3.3270.3 2.8470.3
Baseline values prior to first administration of double-blind study drug.
yValues are presented as no. (%) or mean7SE.
zrp0.050 vs. Z 1600mg+B 400 mg.
yrp0.050 vs. Z 1600mg+B 400 mg; rp0.050 vs. Pl+B 800mg.
zrp0.050 vs. Z 1600mg+B 400mg.
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Figure 1 Mean (7SE) percent change in FEV1 from baseline to
each double-blind visit.
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Figure 2 Mean (7SE) changes in the morning PEF (L/Min)
values from baseline to each double-blind interval; *Statistically
significant at r ¼ 0.050 vs. Pl+B 800 mg.
B.J. O’Connor et al.1092Asthma symptom scores and concurrent treatment
There were statistically significant improvements from
baseline in mean daytime symptom assessments in all the
3 study groups (rp0.001). There were no statistically
significant differences between any 2 treatment groups at
any interval (Fig. 4).
While baseline mean nocturnal symptom scores were mild
in all the 3 treatment groups, (ranging from 0.45 to 0.56)
there were no statistically significant differences between
any 2 treatment groups in mean changes at any interval.
While there were no statistically significant differences
between any 2 treatment groups in mean number of
symptom-free days (mean values ranged from 19 to 22),there was a statistically significant difference in mean
number of symptom-free nights between the Z 2400mg+B
400 mg group (45 nights) and Pl+B 800 mg treatment groups
(59 nights; rp0.050).
The mean daily number of occasions of salbutamol use
generally decreased from baseline values in all treatment
groups during all study intervals, although the differences
were not statistically significant for the Z 2400mg+B 400 mg
group until the Day 58–99 interval.
Twelve patients required a single course of oral or
injected corticosteroids for asthma exacerbations during
the study; 5 in the Z 2400mg+B 400 mg group, 4 in the Z
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Figure 3 Mean (7SE) changes in the evening PEF (L/Min)
values from baseline to each double-blind interval; *Statistically
significant at p ¼ 0.050 vs. Pl+B 800 mg.
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Figure 4 Mean (7SE) changes in daytime symptom scores [0
(none)–3 (severe)] from baseline to each double-blind interval;
decreases in scores indicate improvement.
Table 3 Treatment-related adverse events occurring in X5% o
study.
Adverse event (COSTART
terms)
Z 2400mg+B 400 mg (n ¼ 108)
Infection 25 (23)
Aggravation reactiony 20 (19)
Headache 22 (20)
Rhinitis 12 (11)
Flu syndrome 11 (10)
Dyspepsia 7 (7)
Pharyngitis 2 (2)
Nausea 6 (6)
Values are presented as no. (%)
yThe adverse event described by the COSTART term, ‘‘Aggravation
which was an exacerbation of eczema.
Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma 10931600mg+B 400 mg group, and 3 in the Pl+B 800 mg group.
Eight patients withdrew from the study due to an asthma
exacerbation; 3 in the Z 2400mg+B 400 mg group, 3 in the Z
1600mg+B 400 mg group and 2 in the Pl+B 800 mg group.
There were no statistically significant differences in the
number of acute exacerbations or the number of patients
requiring corticosteroids (oral or injected) between any of
the treatment groups.Safety
Adverse events (Table 3) were similar across all groups.
Results of laboratory tests physical examinations, electro-
cardiograms, and chest radiographs were unremarkable with
the exception of liver function abnormalities.
Five patients had alanine aminotransferase (ALT) values
ofX2 times the upper limit of normal (X2ULN); 2 in the Z
2400mg+B 400 mg group, 2 in the Z 1600mg+B 400 mg group,
and 1 in the Pl+B 800 mg group. Of the 4 patients taking
zileuton who had ALT values X2ULN, 2 (1 in each group)
had values that returned to normal while patients continued
treatment and in the other 2 cases (1 in each group),
resolution occurred within 20 days after discontinuation of
the study drug. Only 1 patient (Z 2400mg+B 400 mg
treatment group) had an increase that was X3ULN
and this elevation resolved upon discontinuation of the
study drug.Discussion
While the addition of a 5-LO inhibitor, zileuton (400 or
600mg QID), to a low-dose ICS, BDP (200mg BID), did not
show significant differences in FEV1 when compared to
doubling the dose of BDP after 3 months of therapy, there
were significant improvements in lung function and asthma
symptoms within each treatment group compared to base-
line values. The additive effect of zileuton to low-dose
inhaled BDP resulted in rapid and sustained improvements in
all the subjective and objective treatment outcomes
evaluated throughout the study.f any treatment group during the double-blind phase of the
Z 1600mg+B 400 mg (n ¼ 110) Pl+B 800 mg (n ¼ 102)
14 (13) 17 (17)
26 (24) 17 (17)
22 (20) 18 (18)
6 (6) 6 (6)
7 (6) 5 (5)
1 (1) 4 (4)
2 (2) 6 (6)
3 (3) 5 (5)
Reaction,’’ were exacerbations of asthma in all cases but one,
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was associated with a reduction in the use of concomitant
medications including rescue b2-agonists and systemic
corticosteroids for needed for asthma exacerbations. While
the study did not demonstrate significant differences
between treatment groups in the primary outcome of
FEV1, significant improvements in PEF were found in the
2400mg zileuton group. Thus, the addition of zileuton to
low-dose BDP may be an alternative to using higher-doses of
ICS in patients unable to achieve asthma control on low-dose
ICS therapy.
The treatment effects are comparable to the effects seen
in studies with the combination of ICS and LABA in
symptomatic asthmatics.7 Cysteinyl leukotriene receptor
antagonists (LTRA’s) have also shown benefit when added to
inhaled steroids in similarly designed studies33,34 and the
improvements with the 5-LO inhibitor zileuton compare
favorably with those results. Another group has demon-
strated that in a well-controlled, aspirin-intolerant asth-
matic population, in which patients were on medium to high
doses of inhaled and, in some cases, oral steroids, the
addition of zileuton for 6 weeks resulted in acute and
sustained improvements in pulmonary function and im-
proved symptom control similar to the results seen in this
study.47 Additionally a year-long, uncontrolled, open-label
study and several case-reports have demonstrated addi-
tional symptom control and lung function improvement
when zileuton was added to the patients’ current steroid
therapy.34,43,48–52 These data suggest a complimentary
effect between corticosteroids and agents that modulate
leukotriene production.
The improvements in symptom control with zileuton
added to BDP occurred within 2–3 weeks and this relatively
rapid improvement may lead to improved patient compli-
ance with controller regimens. Lung function also improved
throughout the study and this continued improvement may
be due to both zileuton and BDP suggesting a potential
synergism of these 2 therapies.
ICS provide effective long-term control for asthma
patients, but they demonstrate a relatively flat dose-
response with regard to lung function improvement; higher
doses potentially lead to increased unwanted systemic
effects.5 Therefore, optimizing safety and efficacy to
achieve asthma control is ideal. Additionally, inhaled and
oral corticosteroids do not inhibit the in-vivo synthesis of
leukotrienes.29,33,48,49 Indeed, asthmatics on high-dose
inhaled and oral corticosteroids have shown persistently
elevated levels of key 5-LO products, including LTB4, LTC4,
LTD4, and LTE4
27–29,42,50 A recent report demonstrated that
2 weeks of treatment with a potent ICS (fluticasone 500 mg
BID) reduced bronchial responsiveness to methacholine and
decreased exhaled nitric oxide (eNO) levels but had no
effect on bronchial responsiveness to inhaled LTD4, suggest-
ing that leukotriene-dependent parts of bronchoconstriction
and airway inflammation are resistant to the effects of
glucocorticosteroids.51 Because of the relative resistance of
the 5-LO pathway to suppression by corticosteroids, the
addition of a 5-LO inhibitor provides the possibility of
additional asthma control.
Another complementary approach to the use of steroids in
asthma therapy is to modulate leukotriene produc-
tion.13–23,32–34 Leukotrienes are major mediators of theunderlying inflammatory process in asthma. Leukotrienes
can produce bronchoconstriction,13 increased microvascu-
lature permeability, mucus hypersecretion, smooth muscle
hypertrophy and inflammatory cell infiltration including
neutrophils and eosinphils.14 Leukotrienes are produced by
multiple inflammatory cells, particularly mast cells, baso-
phils, eosinophils, neutrophils, and macrophages, all of
which have been implicated in asthma pathogenesis.15–20
The number and state of activation of eosinophils and mast
cells, both rich sources of leukotrienes, correlate with
asthma severity.21,22
Leukotrienes are important mediators in asthma patho-
genesis13–17,23,53 and 5-LO products have been shown to be
increased in all severities of asthma, despite treatment with
inhaled and oral corticosteroids.27–30
Interestingly, steroid therapy has been shown to prolong
the survival of neutrophils which have been suggested to be
important in asthma pathology, especially in more severe
and difficult-to-control patients.27,28,31,32 LTB4, a key
product of the 5-LO pathway, is a potent neutrophil
chemoattractant and levels of LTB4 remain high in the BAL
fluid and urine from severe asthmatics, despite oral and
inhaled steroid therapy.27–31 Therefore, modulating leuko-
triene production with 5-LO inhibition, in conjunction with
ICS, may prove to be a useful complimentary therapeutic
approach to achieving asthma control. This approach may
allow for the blunting of leukotriene-mediated cellular
inflammation, including the effects of LTB4 on neutrophil
chemoattraction.
The incidence and types of adverse events were compar-
able in the 3 treatment groups. Five patients had elevations
of ALTX2ULN, including 1 patient in the placebo group.
Only 1 patient (Z 2400mg+B 400 mg) had an increase
X3ULN and this elevation resolved after discontinuation
of the study drug. Similar findings were seen with zileuton
treatment in previous placebo-controlled studies and
routine ALT monitoring is recommended with zileuton
therapy as well as avoidance in patients with a history of
liver disease.44,45
In conclusion, the addition of a 5-LO inhibitor, zileuton
(400 or 600mg QID), to a low-dose ICS, BDP (200mg BID),
may be an alternative to higher-doses of ICS in patients
unable to achieve sufficient asthma control on low-dose ICS
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